ABION Presents Preclinical Data Showing IFN-β Antibody Fusion ABN202 Outperforms TROP2-Targeting ADCs

Next-generation immuno-oncology candidate demonstrates superior anti-cancer mechanism and potential to overcome resistance to existing ADC therapies

Apr. 7, 2026 at 7:26am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the intricate molecular structure of a novel immuno-oncology drug candidate, conceptually illustrating its potential to disrupt cancer biology.A novel immuno-oncology approach combines antibody-based targeting and cytokine-driven immune activation to overcome resistance to existing cancer therapies.San Diego Today

ABION, a precision oncology therapeutics developer, announced that its next-generation immuno-oncology candidate, ABN202, demonstrated a superior anti-cancer mechanism compared with TROP2-targeting antibody-drug conjugates (ADCs) in preclinical studies. The findings will be presented at the American Association for Cancer Research (AACR) conference, highlighting ABN202's potential to overcome resistance associated with existing ADC therapies and its promise as a new treatment option for patients with solid tumors.

Why it matters

The development of new immuno-oncology strategies that can overcome resistance to current ADC therapies is crucial for improving treatment options and outcomes for cancer patients. ABION's ABN202 represents a novel approach that combines direct tumor cell killing with robust immune activation, potentially addressing a significant unmet need in the oncology landscape.

The details

ABN202 is a next-generation immuno-oncology drug candidate based on ABION's proprietary iRAC (Interferon-β Antibody Conjugate) platform. In preclinical studies, ABN202 demonstrated superior anti-tumor efficacy compared to TROP2-targeting ADCs, even when combined with anti-PD-1 immune checkpoint inhibitors. Additionally, ABN202 induced sustained and systemic CD8-positive T cell-mediated immune responses, suggesting the potential for durable anti-tumor immunity.

  • The findings will be presented as a poster at the American Association for Cancer Research (AACR 2026) conference, to be held April 17–22 in San Diego, USA.
  • ABION is accelerating the preclinical development of ABN202 toward an IND submission in the first half of next year.

The players

ABION

A precision oncology therapeutics developer that is advancing the preclinical development of its next-generation immuno-oncology candidate, ABN202.

ABN202

ABION's next-generation immuno-oncology drug candidate based on the company's proprietary iRAC (Interferon-β Antibody Conjugate) platform, designed to enable both direct tumor cell killing and robust immune activation.

TROP2-targeting ADCs

Antibody-drug conjugates that target the TROP2 protein, which is overexpressed in various solid tumors.

Got photos? Submit your photos here. ›

What they’re saying

“These results highlight the potential of a differentiated IFN-β-based immuno-oncology strategy to overcome resistance to current ADC therapies. Based on these encouraging preclinical findings, we are also actively exploring strategic partnership opportunities for ABN202, including collaborations at the preclinical stage.”

— Dr. Young Kee Shin, CEO/CTO of ABION

What’s next

ABION is accelerating the preclinical development of ABN202 toward an IND submission in the first half of next year, positioning the candidate as a potential game changer in oncology.

The takeaway

ABION's novel immuno-oncology approach with ABN202 has the potential to overcome the limitations of current ADC therapies, offering a promising new treatment option for cancer patients who have failed prior ADC-based therapies. The versatility of ABION's iRAC platform also suggests opportunities for further pipeline expansion and strategic partnerships.